» Authors » Mami Morita

Mami Morita

Explore the profile of Mami Morita including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 31
Citations 320
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Nomura M, Ohuchi M, Sakamoto Y, Kudo K, Yaku K, Soga T, et al.
Nat Commun . 2023 Dec; 14(1):8095. PMID: 38092728
Nicotinamide phosphoribosyltransferase (NAMPT) plays a major role in NAD biosynthesis in many cancers and is an attractive potential cancer target. However, factors dictating therapeutic efficacy of NAMPT inhibitors (NAMPTi) are...
2.
Ito S, Tsurumi K, Shindo N, Soma S, Yamaguchi K, Tamai K, et al.
Anticancer Res . 2023 Nov; 43(11):5031-5040. PMID: 37909987
Background/aim: Osimertinib is currently used as a first-line treatment for EGFR-mutated non-small cell lung cancer, and the emergence of drug resistance poses a substantial challenge. Liquid biopsy with a multi-gene...
3.
Fukuhara T, Imai K, Nakagawa T, Igusa R, Yokota H, Watanabe K, et al.
Biomedicines . 2023 Sep; 11(9). PMID: 37760942
Osimertinib is a standard treatment for patients with EGFR-mutated non-small cell lung carcinoma (NSCLC). We evaluated the relationship between plasma osimertinib concentrations and treatment outcome in patients with NSCLC for...
4.
5.
Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, et al.
Int J Clin Oncol . 2021 Oct; 27(1):112-120. PMID: 34643820
Background: Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, its effectiveness and safety...
6.
Miyauchi E, Tanaka H, Nakamura A, Harada T, Nakagawa T, Morita M, et al.
Thorac Cancer . 2021 Sep; 12(21):2886-2893. PMID: 34523232
Background: NJLCG1402 was a phase I/II trial investigating biweekly nanoparticle albumin-bound paclitaxel (nab-PTX) in patients with advanced non-small cell lung cancer (NSCLC). Methods: The study included patients aged ≥20 years...
7.
Niimi K, Yamamoto E, Morita S, Morikawa M, Hattori H, Hatakeyama M, et al.
Mol Clin Oncol . 2021 Jun; 15(1):143. PMID: 34094541
Gestational choriocarcinoma is a gestational trophoblastic neoplasia (GTN) originating from trophoblastic cells with abnormal proliferation. Although chemotherapy is effective for treating this cancer, when patients develop chemoresistance, personalized treatment, such...
8.
Morita M, Kudo K, Shima H, Tanuma N
Cancer Sci . 2020 Dec; 112(2):498-504. PMID: 33340176
Cancer metabolism is influenced by availability of nutrients in the microenvironment and can to some extent be manipulated by dietary modifications that target oncogenic metabolism. As yet, few dietary interventions...
9.
Kikuchi N, Soga T, Nomura M, Sato T, Sakamoto Y, Tanaka R, et al.
Biochem Biophys Res Commun . 2020 Aug; 530(1):285-291. PMID: 32828300
Recent advances in cancer biology reveal the importance of metabolic changes in cancer; however, less is known about how metabolic pathways in tumors are regulated in vivo. Here, we report...
10.
Kudo K, Nomura M, Sakamoto Y, Ito S, Morita M, Kawai M, et al.
FEBS Lett . 2020 Jan; 594(9):1379-1388. PMID: 31950503
It is of current interest to target cancer metabolism as treatment for many malignancies, including ovarian cancer (OVC), in which few druggable driver mutations have been identified. Nicotinamide phosphoribosyltransferase (NAMPT),...